NO20052408L - Farmasoytisk formulering av olanzapin - Google Patents
Farmasoytisk formulering av olanzapinInfo
- Publication number
- NO20052408L NO20052408L NO20052408A NO20052408A NO20052408L NO 20052408 L NO20052408 L NO 20052408L NO 20052408 A NO20052408 A NO 20052408A NO 20052408 A NO20052408 A NO 20052408A NO 20052408 L NO20052408 L NO 20052408L
- Authority
- NO
- Norway
- Prior art keywords
- olanzapine
- pharmaceutical formulation
- monosaccharide
- oligosaccharide
- polysaccharide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
En farmasøytisk formulering omfattende en homogen blanding av (a) olanzapin eller et farmasøytisk akseptabelt salt av derme som aktiv ingrediens, (b) et monosakkarid og/eller ohgosakkarid, (c) et polysakkarid og eventuelt ytterligere ingredienser.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200200255A SI21303A (sl) | 2002-10-18 | 2002-10-18 | Farmacevtska formulacija olanzapina |
PCT/SI2003/000036 WO2004035027A1 (en) | 2002-10-18 | 2003-10-16 | Pharmaceutical formulation of olanzapine |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20052408D0 NO20052408D0 (no) | 2005-05-13 |
NO20052408L true NO20052408L (no) | 2005-07-04 |
Family
ID=32173824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20052408A NO20052408L (no) | 2002-10-18 | 2005-05-13 | Farmasoytisk formulering av olanzapin |
Country Status (18)
Country | Link |
---|---|
US (2) | US20050288276A1 (no) |
EP (1) | EP1558219B1 (no) |
AT (1) | ATE374600T1 (no) |
AU (1) | AU2003269792A1 (no) |
CA (1) | CA2502582C (no) |
CY (1) | CY1107819T1 (no) |
DE (1) | DE60316714T2 (no) |
DK (1) | DK1558219T3 (no) |
EA (1) | EA008516B1 (no) |
ES (1) | ES2295626T3 (no) |
HR (1) | HRP20050342B1 (no) |
NO (1) | NO20052408L (no) |
PL (1) | PL206217B1 (no) |
PT (1) | PT1558219E (no) |
RS (1) | RS51488B (no) |
SI (2) | SI21303A (no) |
UA (1) | UA89349C2 (no) |
WO (1) | WO2004035027A1 (no) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060063737A1 (en) * | 2004-08-18 | 2006-03-23 | Holmdahl Lisa K | Liquid paroxetine compositions |
CZ297214B6 (cs) * | 2005-02-02 | 2006-10-11 | Zentiva, A. S. | Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby |
GB0522473D0 (en) * | 2005-11-03 | 2005-12-14 | Actavis Group | A pharmaceutical formulation |
GB0522474D0 (en) * | 2005-11-03 | 2005-12-14 | Actavis Group | A pharmaceutical formulation |
ES2279715B1 (es) | 2005-12-26 | 2008-06-01 | Laboratorios Lesvi, S.L. | Formulacion oral de olanzapina. |
US20070293479A1 (en) * | 2006-05-18 | 2007-12-20 | Osinga Niels J | Olanzapine pharmaceutical composition |
US20080138409A1 (en) * | 2006-09-29 | 2008-06-12 | Osinga Niels J | Olanzapine pharmaceutical composition |
WO2012014012A1 (es) * | 2010-07-27 | 2012-02-02 | Laboratorios Andrómaco S.A. | Procedimiento para preparar comprimidos de disolucion rapida oral que comprenden la forma i de olanzapina, los comprimidos obtenidos y su uso para el tratamiento de la esquizofrenia. |
WO2012153347A2 (en) | 2011-05-04 | 2012-11-15 | Zentiva K.S. | Oral pharmaceutical composition of olanzapine form 1 |
WO2013066280A1 (en) * | 2011-10-31 | 2013-05-10 | Mahmut Bilgic | Water soluble antipsychotic formulations |
CN103919782B (zh) * | 2013-01-15 | 2016-12-28 | 天津药物研究院有限公司 | 一种含有奥氮平的药物组合物及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2083622B1 (no) * | 1970-03-27 | 1975-08-22 | Sankyo Co | |
GB9009229D0 (en) | 1990-04-25 | 1990-06-20 | Lilly Industries Ltd | Pharmaceutical compounds |
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
ID21762A (id) * | 1996-09-24 | 1999-07-22 | Lilly Co Eli | Formulasi partikel bersaput |
US6348458B1 (en) * | 1999-12-28 | 2002-02-19 | U & I Pharmaceuticals Ltd. | Polymorphic forms of olanzapine |
JP4530664B2 (ja) * | 2001-12-24 | 2010-08-25 | サン・ファーマシューティカル・インダストリーズ・リミテッド | 2−メチル−4−(4−メチル−1−ピペラジニル)−10H−チエノ[2,3−b][1,5]ベンゾジアゼピンの結晶形I、この結晶形Iの製造方法、及び医薬組成物 |
AU2002255196A1 (en) * | 2002-04-18 | 2003-10-27 | Dr. Reddy's Laboratories Ltd. | Rapidly dispersing solid oral compositions |
-
2002
- 2002-10-18 SI SI200200255A patent/SI21303A/sl not_active IP Right Cessation
-
2003
- 2003-10-16 RS YUP-2005/0292A patent/RS51488B/en unknown
- 2003-10-16 DK DK03751723T patent/DK1558219T3/da active
- 2003-10-16 PT PT03751723T patent/PT1558219E/pt unknown
- 2003-10-16 CA CA2502582A patent/CA2502582C/en not_active Expired - Fee Related
- 2003-10-16 ES ES03751723T patent/ES2295626T3/es not_active Expired - Lifetime
- 2003-10-16 UA UAA200504641A patent/UA89349C2/uk unknown
- 2003-10-16 EA EA200500671A patent/EA008516B1/ru not_active IP Right Cessation
- 2003-10-16 US US10/531,540 patent/US20050288276A1/en not_active Abandoned
- 2003-10-16 AU AU2003269792A patent/AU2003269792A1/en not_active Abandoned
- 2003-10-16 AT AT03751723T patent/ATE374600T1/de active
- 2003-10-16 SI SI200331001T patent/SI1558219T1/sl unknown
- 2003-10-16 EP EP03751723A patent/EP1558219B1/en not_active Revoked
- 2003-10-16 WO PCT/SI2003/000036 patent/WO2004035027A1/en active IP Right Grant
- 2003-10-16 DE DE60316714T patent/DE60316714T2/de not_active Expired - Lifetime
- 2003-10-16 PL PL376413A patent/PL206217B1/pl unknown
-
2005
- 2005-04-15 HR HRP20050342AA patent/HRP20050342B1/hr not_active IP Right Cessation
- 2005-05-13 NO NO20052408A patent/NO20052408L/no not_active Application Discontinuation
-
2007
- 2007-12-03 CY CY20071101537T patent/CY1107819T1/el unknown
-
2011
- 2011-09-08 US US13/228,028 patent/US20110319395A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HRP20050342B1 (hr) | 2013-11-08 |
RS51488B (en) | 2011-04-30 |
DK1558219T3 (da) | 2007-10-29 |
WO2004035027A1 (en) | 2004-04-29 |
RS20050292A (en) | 2007-08-03 |
EA008516B1 (ru) | 2007-06-29 |
EA200500671A1 (ru) | 2005-10-27 |
UA89349C2 (uk) | 2010-01-25 |
EP1558219A1 (en) | 2005-08-03 |
ES2295626T3 (es) | 2008-04-16 |
PT1558219E (pt) | 2008-01-04 |
CA2502582C (en) | 2010-08-03 |
NO20052408D0 (no) | 2005-05-13 |
PL206217B1 (pl) | 2010-07-30 |
HRP20050342A2 (hr) | 2006-04-30 |
PL376413A1 (en) | 2005-12-27 |
CA2502582A1 (en) | 2004-04-29 |
CY1107819T1 (el) | 2013-06-19 |
AU2003269792A1 (en) | 2004-05-04 |
SI1558219T1 (sl) | 2008-02-29 |
DE60316714D1 (de) | 2007-11-15 |
EP1558219B1 (en) | 2007-10-03 |
US20110319395A1 (en) | 2011-12-29 |
US20050288276A1 (en) | 2005-12-29 |
ATE374600T1 (de) | 2007-10-15 |
SI21303A (sl) | 2004-04-30 |
DE60316714T2 (de) | 2008-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107819T1 (el) | Φαρμακευτικη διαμορφωση της ολανζαπινης | |
NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
DK1207756T3 (da) | Anvendelse af spinosad eller en formulering, der omfatter spinosad | |
EP1589947B8 (en) | Pharmaceutical formulation with an insoluble active agent for pulmonary administration | |
HUP0203451A2 (hu) | Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra | |
ATE292453T1 (de) | Antivirale arznei | |
MXPA03008420A (es) | Forma farmaceutica solida oralmente dispersa. | |
WO2005065639A3 (en) | Novel pharmaceutical compositions | |
HUP0500842A2 (hu) | Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra | |
MXPA05013270A (es) | Forma de administracion transmucosal con irritacion mucosal reducida. reducida. | |
WO2005065648A3 (en) | Novel drug compositions and dosage forms of topiramate | |
NO20054417L (no) | Fremgangsmate for fremstilling av farmasoytiske preperater i form av fibratholdige tabletter og de derved fremstilte tabletter | |
NO20051261L (no) | Morfin-6-glukuronidsalt | |
WO2004069187A3 (en) | Drug formulation and delivery using crystalline methylated cyclodextrins | |
TR200301553A1 (tr) | İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar | |
EA200601015A1 (ru) | Пероральные композиции дезоксипеганина и их применение | |
WO2004033484A3 (en) | Use of stable glutamine derivatives to improve drug absorption | |
AU2001260089A1 (en) | Pharmaceutical compositions comprising desglymidodrine as an active drug substance | |
HRP20050466A2 (en) | Pharmaceutical composition comprising a ltb4 antagonists and a cox-2 inhibitor or a combined cox 1/2 inhibitor | |
NO20021527D0 (no) | Pyrimidinderivater, fremgangsmåte for fremstilling av derivatene og legemidler inneholdende de samme som den aktivebestanddel | |
WO2002041875A3 (de) | Verfahren zur herstellung leicht löslicher arzneimittelformulierungen und entsprechende formulierungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |